Table 3. Mohs Surgery Performed on Keratinocyte Carcinomas During the Triala.
| Time Period | Fluorouracil | Control | Risk Ratio (95% CI) | P Value |
|---|---|---|---|---|
| KCs Treated With Mohs Surgery | ||||
| Year 1 | 20 | 41 | 0.72 (0.48-1.10) | .11 |
| Overall study period | 153 | 149 | 1.07 (0.91-1.26) | .43 |
| Participants With ≥1 KC Treated With Mohs Surgery | ||||
| Year 1 | 16 | 31 | 0.51 (0.28-0.92) | .02 |
| Overall study period | 101 | 92 | 1.09 (0.85-1.40) | .51 |
| BCCs Treated With Mohs Surgery | ||||
| Year 1 | 17 | 36 | 0.56 (0.36-0.89) | .01 |
| Overall study period | 120 | 118 | 1.04 (0.86-1.25) | .69 |
| Participants With ≥1 BCC Treated With Mohs Surgery | ||||
| Year 1 | 14 | 27 | 0.51 (0.27-0.97) | .045 |
| Overall study period | 87 | 79 | 1.09 (0.84-1.44) | .53 |
Abbreviations: BCC, basal cell carcinoma; KC, keratinocyte carcinoma; SCC, squamous cell carcinoma.
a
In the fluorouracil group, 149 KCs (120 BCCs and 29 SCCs) were treated with Mohs surgery during the overall study; 20 of these (17 BCCs and 3 SCCs) in year 1. In the control group, 149 KCs (118 BCCs and 31 SCCs) were treated with Mohs surgery during the overall study; 41 of these (36 BCCs and 5 SCCs) in year 1. The number of SCCs treated with Mohs in year 1 was too small to further analyze. In the overall study, there was no difference in risk of SCC treated with Mohs in the fluorouracil vs the control group (data not shown).